Wedbush Downgrades Regado Biosciences to Underperform (RGDO)
A number of other analysts have also recently weighed in on RGDO. Analysts at Jefferies Group initiated coverage on shares of Regado Biosciences in a research note on Wednesday, June 11th. They set a “buy” rating and a $14.00 price target on the stock. Separately, analysts at Needham & Company LLC cut their price target on shares of Regado Biosciences from $16.00 to $13.00 in a research note on Thursday, May 15th. They now have a “buy” rating on the stock. Finally, analysts at Deutsche Bank initiated coverage on shares of Regado Biosciences in a research note on Friday, April 25th. They set a “buy” rating and a $14.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $13.80.
Shares of Regado Biosciences (NASDAQ:RGDO) opened at 6.76 on Thursday. Regado Biosciences has a 1-year low of $4.27 and a 1-year high of $14.10. The stock has a 50-day moving average of $6.35 and a 200-day moving average of $7.10. The company’s market cap is $227.2 million.
Regado Biosciences (NASDAQ:RGDO) last announced its earnings results on Wednesday, May 14th. The company reported ($1.30) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.62) by $0.68. Analysts expect that Regado Biosciences will post $-2.18 EPS for the current fiscal year.
Regado Biosciences, Inc is a biopharmaceutical company focused on the discovery and development of actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.